CytomX Therapeutics (CTMX) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
CytomX Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 4 sold $1.7M of CTMX stock on the open market.
Get emailed when insiders cluster-buy stocks like CTMX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CTMX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $5K | 1 |
| Q1 2026 | — | 0 | $1.2M | 4 |
| Q4 2025 | — | 0 | $462K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 CytomX Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 4 insiders reported sales totaling $1.7M. 2 of 6 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 17SEC | Christopher OgdenCFO | Sell | 1,624295,324 held (−1%) | $3.05 | $5K | -15.7% | — |
| Mar 19SEC | Sean A. MccarthyCEO | Sell Plan | 118,9691,078,922 held (−10%) | $6.42 | $764K | -60.0% | — |
| Mar 19SEC | Marcia BelvinSvp, Chief Scientific Officer | Sell | 31,492300,760 held (−9%) | $6.42 | $202K | -60.0% | — |
| Mar 19SEC | Yu-waye ChuChief Medical Officer | Sell | 21,279189,446 held (−10%) | $6.42 | $137K | -60.0% | — |
| Mar 19SEC | Christopher OgdenCFO | Sell | 19,323296,948 held (−6%) | $6.42 | $124K | -60.0% | — |
| Nov 10SEC | Sean A. MccarthyCEO | Sell Plan | 101,793987,891 held (−9%) | $4.54 | $462K | -43.4% | — |
Insiders at CytomX Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Sean A. MccarthyCEO | — | $1.2M | Mar 19, 2026 | — |
| Marcia BelvinSvp, Chief Scientific Officer | — | $202K | Mar 19, 2026 | — |
| Yu-waye ChuChief Medical Officer | — | $137K | Mar 19, 2026 | — |
| Christopher OgdenCFO | — | $129K | Jun 17, 2026 | — |
CTMX stock: common questions
Are CytomX Therapeutics, Inc. insiders buying CTMX stock?
In the past 12 months, 0 insiders reported open-market purchases of CTMX worth $0.
Are CytomX Therapeutics, Inc. insiders selling CTMX stock?
4 insiders reported sales worth $1.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CTMX's 52-week range?
Over the past year CTMX has traded between $2.47 and $6.75. It last closed at $2.57 on Oct 9, 2026.